Akero Therapeutics Inc

General ticker "AKRO" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $2.1B

Akero Therapeutics Inc follows the US Stock Market performance with the rate: 56.0%.

Estimated limits based on current volatility of 3.5%: low 27.86$, high 29.89$

Factors to consider:

  • Price in estimated range
  • Earnings for 18 months up through Q2 (+1 year) are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2022-12-31 to 2024-12-30

  • 2022-12-31 to 2023-12-31 estimated range: [21.44$, 46.64$]
  • 2023-12-31 to 2024-12-30 estimated range: [16.03$, 36.27$]

Financial Metrics affecting the AKRO estimates:

  • Negative: Non-GAAP EPS, $ of -2.92 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -5.07 <= 2.35
  • Negative: negative Net income
  • Positive: Interest expense per share, $ of 0.02 <= 0.14
  • Positive: Inventory ratio change, % of 0 <= 0

Similar symbols

Short-term AKRO quotes

Long-term AKRO plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $100.89MM $115.16MM $172.87MM
Operating Income $-100.89MM $-115.16MM $-172.87MM
Non-Operating Income $0.11MM $3.12MM $21.11MM
Interest Expense $0.00MM $0.74MM $3.10MM
R&D Expense $81.76MM $85.28MM $141.80MM
Income(Loss) $-100.78MM $-112.03MM $-151.76MM
Profit(Loss) $-100.78MM $-112.03MM $-151.76MM
Stockholders Equity $169.11MM $326.56MM $535.31MM
Assets $195.55MM $356.57MM $580.27MM
Operating Cash Flow $-79.68MM $-92.52MM $-145.37MM
Investing Cash Flow $42.28MM $-63.83MM $-223.62MM
Financing Cash Flow $0.60MM $255.63MM $353.32MM
Earnings Per Share* $-2.89 $-2.79 $-2.89

* EPS are Split Adjusted, recent splits may be reflected with a delay.